G1 Therapeutics (NASDAQ:GTHX) Lowered to Sell at Zacks Investment Research

G1 Therapeutics (NASDAQ:GTHXGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price objective on shares of G1 Therapeutics in a research note on Thursday, April 14th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $37.00.

GTHX stock traded down $0.47 during trading on Tuesday, reaching $5.93. The stock had a trading volume of 768,077 shares, compared to its average volume of 792,710. G1 Therapeutics has a 52 week low of $5.91 and a 52 week high of $24.12. The stock’s 50 day moving average is $8.46 and its two-hundred day moving average is $10.57. The company has a current ratio of 8.82, a quick ratio of 8.69 and a debt-to-equity ratio of 0.52. The firm has a market cap of $253.25 million, a PE ratio of -1.68 and a beta of 1.93.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last posted its earnings results on Wednesday, February 23rd. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.09. G1 Therapeutics had a negative return on equity of 76.03% and a negative net margin of 471.32%. The company had revenue of $5.80 million for the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the prior year, the company earned ($0.67) earnings per share. On average, research analysts anticipate that G1 Therapeutics will post -3.75 EPS for the current year.

Large investors have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in G1 Therapeutics by 69.0% during the third quarter. Royal Bank of Canada now owns 5,254 shares of the company’s stock valued at $71,000 after purchasing an additional 2,145 shares in the last quarter. Ensign Peak Advisors Inc purchased a new position in G1 Therapeutics during the fourth quarter valued at approximately $79,000. Point72 Hong Kong Ltd purchased a new position in G1 Therapeutics during the third quarter valued at approximately $85,000. BNP Paribas Arbitrage SA lifted its holdings in G1 Therapeutics by 479.1% during the third quarter. BNP Paribas Arbitrage SA now owns 7,772 shares of the company’s stock valued at $104,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Guggenheim Capital LLC purchased a new position in G1 Therapeutics during the fourth quarter valued at approximately $106,000. 63.73% of the stock is currently owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile (Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Further Reading

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.